Erste Asset Management GmbH Acquires Shares of 21,153 STAAR Surgical (NASDAQ:STAA)

Erste Asset Management GmbH bought a new position in shares of STAAR Surgical (NASDAQ:STAA - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,153 shares of the medical instruments supplier's stock, valued at approximately $788,000.

Several other large investors have also modified their holdings of the business. Geneva Capital Management LLC grew its position in shares of STAAR Surgical by 0.3% in the third quarter. Geneva Capital Management LLC now owns 695,415 shares of the medical instruments supplier's stock valued at $25,835,000 after purchasing an additional 2,241 shares during the last quarter. Defender Capital LLC. raised its stake in STAAR Surgical by 4.4% during the third quarter. Defender Capital LLC. now owns 677,617 shares of the medical instruments supplier's stock worth $25,173,000 after purchasing an additional 28,430 shares during the period. Kayne Anderson Rudnick Investment Management LLC raised its stake in STAAR Surgical by 50.1% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 592,621 shares of the medical instruments supplier's stock worth $28,215,000 after purchasing an additional 197,717 shares during the period. American Capital Management Inc. lifted its holdings in shares of STAAR Surgical by 42.9% during the 3rd quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier's stock valued at $19,051,000 after acquiring an additional 154,037 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of STAAR Surgical by 25.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 459,655 shares of the medical instruments supplier's stock valued at $21,884,000 after acquiring an additional 94,422 shares in the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a research note on Thursday, October 31st. Stifel Nicolaus dropped their target price on shares of STAAR Surgical from $50.00 to $44.00 and set a "buy" rating for the company in a research report on Monday, August 26th. Finally, Canaccord Genuity Group dropped their target price on shares of STAAR Surgical from $41.00 to $31.00 and set a "hold" rating for the company in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $43.33.

STAAR Surgical Stock Performance

Shares of NASDAQ:STAA traded down $0.54 during trading on Wednesday, reaching $25.95. The company had a trading volume of 449,417 shares, compared to its average volume of 706,235. The firm's fifty day moving average is $30.41 and its 200 day moving average is $35.84. The firm has a market capitalization of $1.28 billion, a PE ratio of 60.20 and a beta of 0.59. STAAR Surgical has a twelve month low of $25.77 and a twelve month high of $52.68.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.